Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-17 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/01/26	4,550.00 ₩	+1.79%	147,953
09/01/26	4,470.00 ₩	-0.89%	176,599
08/01/26	4,510.00 ₩	-1.31%	130,959
07/01/26	4,570.00 ₩	-1.61%	196,282
06/01/26	4,645.00 ₩	-2.82%	189,990

End-of-day quote Korea S.E., January 08, 2026

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 09/01/2026			5-day change	1st Jan Change
4,470.00 ^KRW	-0.89%		-8.59%	-4.59%

30/09/25	Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd.	CI
22/09/25	Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd.	CI

Capitalization	243B 166M 142M 132M 123M 230M 14.92B 246M 1.52B 597M 7.14B 621M 608M 26.17B	P/E ratio 2022	-8.34x	P/E ratio 2023	-5.99x
Enterprise value	246B 168M 143M 133M 124M 232M 15.1B 249M 1.54B 604M 7.22B 628M 615M 26.49B	EV / Sales 2022	33x	EV / Sales 2023	93.4x
Free-Float	81.23%	Yield 2022 *	-	Yield 2023	-

30/09/25	Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd.	CI
22/09/25	Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd.	CI
07/03/25	Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan	MT
30/09/24	Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc.	CI
04/07/24	Genexine, Inc. Appoints Jaehyun Choi as Head of R&D	CI
25/06/24	Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.	CI
14/05/24	Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/11/23	Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23/10/23	Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	CI
31/08/23	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
31/08/23	Sector Update: Health Care	MT
31/08/23	Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	MT
31/08/23	I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	MT

29/05/23	Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting	AQ
23/01/23	Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer	AQ
25/08/22	Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congr	AQ
21/08/18	Genexine : Ichor Medical Systems Announces Utilization of Its Investigational TriGrid Delivery System in a Clinical Trial Evaluating GX-188E Vaccine Combined with a Checkpoint Inhibitor for Treatment of Cervical Cancer	BU
19/06/17	Genexine : Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA® (pembrolizumab), for the Treatment of HPV-Induced Cervical Cancer	BU

Genexine, Inc. Share Price

Equities

A095700

KR7095700001

Biotechnology & Medical Research

Valuation: Genexine, Inc.

Chart: Genexine, Inc.

Latest news: Genexine, Inc.

Press Releases: Genexine, Inc.

News in other languages: Genexine, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genexine, Inc.

ETFs: Genexine, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

02/12/20	Boryung Pharmaceutical : Varios hackers vinculados a Corea del Norte atacan a J&J y Novavax en busca de datos sobre la COVID-19
02/12/20	Boryung Pharmaceutical : Coronavirus-Des hackers liés à Pyongyang ont visé au moins neuf instituts de santé-sources
02/12/20	Johnson & Johnson : Nordkorea soll sechs Covid-Medikamentenentwickler attackiert haben
02/12/20	AstraZeneca : Hackers norcoreanos atacaron a firmas que trabajan en vacunas Covid-19 -Fuentes

1 day	-0.89%
1 week	-8.59%
Current month	-4.59%
1 month	-12.35%
3 months	-27.44%
6 months	-12.18%
Current year	-4.59%

1 week	4,430	4,830
1 month	4,430	5,030
Current year	4,430	4,950
1 year	3,510	7,190
3 years	3,510	16,840
5 years	3,510	100,769.23
10 years	3,510	146,384.62

Manager	Title	Age	Since
Seong-Joon Hong CEO	Chief Executive Officer	61	26/01/2023
Hyun-Chul Jeon AUD	Comptroller/Controller/Auditor	67	-
Gwang-Ho Kim HRO	Human Resources Officer	63	-

Director	Title	Age	Since
Young-Jin Kim CHM	Chairman	68	-
Jin-Geon Bae BRD	Director/Board Member	74	28/03/2022
Seong-Joon Hong BRD	Director/Board Member	61	26/01/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GENEXINE, INC.	-0.89%	-8.59%	-20.46%	-69.49%	141M
ARGENX SE	+3.72%	+1.99%	+7.79%	+89.66%	48.01B
WUXI APPTEC CO., LTD.	-0.40%	+4.35%	+84.93%	+8.53%	41.97B
INSMED INCORPORATED	-4.69%	-4.27%	+157.04%	+768.57%	35.77B
BIONTECH SE	+2.33%	+5.50%	-16.83%	-31.61%	25.64B
GENMAB A/S	-0.44%	+7.41%	+38.13%	-21.15%	20.81B
WUXI BIOLOGICS (CAYMAN) INC.	+5.85%	+18.68%	+135.38%	-41.71%	19.92B
SUMMIT THERAPEUTICS INC.	-13.41%	-2.29%	-4.54%	+323.88%	13.14B
AKESO, INC.	-4.36%	+2.99%	+117.69%	+162.46%	14.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.68%	+11.30%	+185.68%	-	14.63B
Average	-0.09%	+3.38%	+68.48%	+132.13%	23.49B
Weighted average by Cap.	+0.11%	+2.92%	+72.46%	+166.76%

	2022	2023
Net sales	16.14B 11M 9.42M 8.76M 8.17M 15.26M 991M 16.37M 101M 39.67M 474M 41.25M 40.41M 1.74B	4.43B 3.02M 2.58M 2.4M 2.24M 4.19M 272M 4.49M 27.68M 10.88M 130M 11.31M 11.08M 477M
Net income	-55.97B -38.15M -32.67M -30.38M -28.32M -52.92M -3.44B -56.76M -350M -138M -1.64B -143M -140M -6.03B	-66.87B -45.58M -39.03M -36.3M -33.84M -63.23M -4.11B -67.82M -418M -164M -1.97B -171M -167M -7.21B
Net Debt	62.14B 42.35M 36.27M 33.73M 31.44M 58.75M 3.82B 63.02M 389M 153M 1.83B 159M 156M 6.7B	2.94B 2.01M 1.72M 1.6M 1.49M 2.78M 181M 2.99M 18.41M 7.24M 86.55M 7.53M 7.37M 317M